TrialJournal for immunotherapy of cancer2022

Antitumor activity and safety of camrelizumab plus famitinib in patients with platinum-resistant recurrent ovarian cancer: results from an open-label, multicenter phase 2 basket study.

Lingfang Xia et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.